Family History.

<p>Family History.</p

Coverage Statistics of the Exome Sequencing Procedure of the Patient.

*<p>On target: mapping to bases included in the array design</p>**<p>Near target: In 500 basepair (approximate fragment length) proximity of array targets</p>***<p>Off target: Mapping to other genomic positions in the genome</p

Posaconazole Treatment Schedule.

<p>Posaconazole Treatment Schedule.</p

Imaging Test and Special Test/Procedure Results.

<p>Imaging Test and Special Test/Procedure Results.</p

WBC, Flow Cytometry (CD4/CD8) Cell, and NK Cell Profile.

<p>WBC, Flow Cytometry (CD4/CD8) Cell, and NK Cell Profile.</p

Caspofungin Treatment Schedule.

<p>Caspofungin Treatment Schedule.</p

Fungal Culture and Sensitivity Testing Results (Prostatic Fluid and Ejaculate).

<p>Fungal Culture and Sensitivity Testing Results (Prostatic Fluid and Ejaculate).</p

Validation of Mutation by Sanger Sequencing.

<p>Validation of Mutation by Sanger Sequencing.</p

Voriconazole Treatment Schedule.

<p>Voriconazole Treatment Schedule.</p

Dynamics of Symptoms over Time.

<p>Rash and sinusitis symptom severity presented on a scale of 0 to 10, with 10 being worst. NIH-CPSI scores presented on the respective scales: NIH-CPSI Pain Domain: 0–21, NIH-CPSI Voiding Domain: 0–10, NIH-CPSI Quality of Life Impact Domain: 0–12 and Total NIH-CPSI Score: 0–43 (from Litwin MS, McNaughton-Collins M, Fowler FJ Jr, Nickel JC, Calhoun EA, <i>et. al</i>. (1999) The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 162∶369-75.</p